Company Overview and News
Gold prices kicked off the New Year in great fashion, logged the best January opening since 2013 andtouched its highest since late September. This move was a continuation of the year-end rally that led the precious metal to jump about 4.4% in the last three weeks of 2017.
The model portfolio continues to generate profits above projection. Since the last update in November, gains for the long/short design have moderated a bit, but are still zigzagging higher. Absent large losses in the Twenty-First Century Fox (FOXA), AT&T (T), Verizon (VZ), Costco (COST) and Nike (NKE) short sale positions the last two months, this portfolio would be up another 3%. Nevertheless, gains in the longs and steady underperformance of the market by the other shorts have generated another 1% in total profits since my last report.
Despite the bullishness in the stock market, gold maintained its sheen this year thanks to geopolitical concerns, instability in Europe and United States as well as lofty stock valuations. This is especially true, as the bullion has risen about 9.2% while the S&P 500 Index has gained 13.2% in the year-to-date time frame. After the fourth consecutive weekly loss, gold price rebounded to a two-week high toward $1,300 per ounce level as uptick in geopolitical uncertainty raised demand for the precious metal as a safe haven.
China and India – once key buyers of gold – are now seeing a plunge in demand, taking global requirement to its lowest level in seven years. Prices remained high on safe-haven bid, especially emanating from North Korea. This is what dealers in India believe buyers are being discouraged by.
Gold prices are glittering again thanks to a subdued greenback and political uncertainty. The largest gold ETF SPDR Gold Shares (GLD - Free Report) has gained about 12% in the year-to-date frame (as of August 11, 2017) and was up about 5.8% in the last one month.
In times of uncertainty, investor demand for safe haven assets rises. Investors flock to safety by dumping riskier assets such as equities (SPY). The safe havens that benefit the most in times of uncertainty include gold (GLD) and U.S. Treasuries (GOVT). After news of escalated tensions between the United States and North Korea hit the markets, riskier assets that have been outperforming in the past month fell dramatically.
Gold prices are back on a rallying mode thanks to subdued greenback and political uncertainty. The largest gold ETF SPDR Gold Shares (GLD - Free Report) has gained about 10.2% in the year-to-date frame (as of July 31, 2017) and was up about 4% in the last one month. Last month’s gain followed gold’s first monthly drop of this year in June (read: Top ETF Stories of July 2017).
Gold prices are back on a rallying mode having returned about 0.7% in the last five days (as of May 23, 2017). The metal was on the wrong end of the Trump-induced market rally at the end of 2016, registering “its second-worst quarter in 18 years.”
Several readers have asked me to explain what a larger hedged portfolio of ideas would look like today. I have mentioned such a design in the majority of my writings. This article outlines a net neutral, for stock market direction, portfolio of blue-chip stocks picked by my Victory Formation system. Basically, it holds a roughly equal dollar amount of short positions to fully offset the longs in the portfolio, and retains a good 20% of net equity in uncorrelated gold/silver positions to hedge equity price swings.
It’s important for investors to know which stocks are closely tied to precious metals and which aren’t. Stocks with higher correlations to precious metals will likely be even more affected by the global indicators that influence precious metals themselves.
It’s crucial to understand which stocks are closely tied to precious metals and which aren’t. Stocks with higher correlations to precious metals will likely be even more affected by the global indicators that influence precious metals themselves.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET